H.C. Wainwright Remains a Buy on Iterum Therapeutics Plc (ITRM)

By Ryan Adsit

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Iterum Therapeutics Plc (ITRMResearch Report) today and set a price target of $17. The company’s shares closed last Monday at $6.81.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 5.6% and a 35.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.

Iterum Therapeutics Plc has an analyst consensus of Moderate Buy, with a price target consensus of $17.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.22 and a one-year low of $4.70. Currently, Iterum Therapeutics Plc has an average volume of 8,156.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents.